Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer

Por Zeng, C, Vangveravong, S, McDunn, J E, Hawkins, W G, Mach, R H
Publicado em 2013

Concurrent Assessment of Hepatic and Intestinal Cytochrome P450 3A Activities Using Deuterated Alfentanil

Por Kharasch, Evan D., Vangveravong, Suwanna, Buck, Nikki, London, Amy, Kim, Thomas, Blood, Jane, Mach, Robert H
Publicado em 2011

Using SV119-Gold Nanocage Conjugates to Eradicate Cancer Stem Cells through a Combination of Photothermal and Chemo Therapies

Por Sun, Tianmeng, Wang, Yi, Wang, Yucai, Xu, Jinbin, Zhao, Xin, Vangveravong, Suwanna, Mach, Robert H., Xia, Younan
Publicado em 2014

SV119-Gold Nanocage Conjugates: A New Platform for Targeting Cancer Cells via Sigma-2 Receptors

Por Wang, Yucai, Xu, Jinbin, Xia, Xiaohu, Yang, Miaoxin, Vangveravong, Suwanna, Chen, Jingyi, Mach, Robert H., Xia, Younan
Publicado no Nanoscale (2011)

Synthesis and Characterization of Selective Dopamine D(2) Receptor Antagonists. 2. Azaindole, Benzofuran, and Benzothiophene Analogs of L-741,626

Por Vangveravong, Suwanna, Taylor, Michelle, Xu, Jinbin, Cui, Jinquan, Calvin, Wesley, Babic, Sonja, Luedtke, Robert R., Mach, Robert H.
Publicado em 2010

Lysosomal Membrane Permeabilization is an Early Event in Sigma-2 Receptor Ligand Mediated Cell Death in Pancreatic Cancer

Por Hornick, John R, Vangveravong, Suwanna, Spitzer, Dirk, Abate, Carmen, Berardi, Francesco, Goedegebuure, Peter, Mach, Robert H, Hawkins, William G
Publicado em 2012

Synthesis and characterization of selective dopamine D(2) receptor ligands using aripiprazole as the lead compound

Por Vangveravong, Suwanna, Zhang, Zhanbin, Taylor, Michelle, Bearden, Melissa, Xu, Jinbin, Cui, Jinquan, Wang, Wei, Luedtke, Robert R., Mach, Robert H.
Publicado em 2011

Functional assays to define agonists and antagonists of the sigma-2 receptor

Por Zeng, Chenbo, Rothfuss, Justin M., Zhang, Jun, Vangveravong, Suwanna, Chu, Wenhua, Li, Shihong, Tu, Zhude, Xu, Jinbin, Mach, Robert H.
Publicado em 2013

Neuroprotective effects of high affinity sigma 1 receptor selective compounds

Por Luedtke, Robert R., Perez, Evelyn, Yang, Shao-Hua, Liu, Ran, Vangveravong, Suwanna, Tu, Zhude, Mach, Robert H., Simpkins, James W.
Publicado em 2011

Evaluation of D2 and D3 Dopamine Receptor Selective Compounds on L-Dopa Dependent Abnormal Involuntary Movements in Rats

Por Kumar, Rakesh, Riddle, Lindsay R., Griffin, Suzy A., Chu, Wenjua, Vangveravong, Suwanna, Neisewander, Janet, Mach, Robert H., Luedtke, Robert R.
Publicado em 2009

Sigma-2 ligands induce tumour cell death by multiple signalling pathways

Por Zeng, C, Rothfuss, J, Zhang, J, Chu, W, Vangveravong, S, Tu, Z, Pan, F, Chang, K C, Hotchkiss, R, Mach, R H
Publicado em 2012

The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine

Por Goedegebuure Peter, Spitzer Dirk, Mitchem Jonathan B, Tu Zhude, Vangveravong Suwanna, Xu Jinbin, Hornick John R, Mach Robert H, Hawkins William G
Publicado em 2010-11-01

The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine

Por Hornick, John R, Xu, Jinbin, Vangveravong, Suwanna, Tu, Zhude, Mitchem, Jonathan B, Spitzer, Dirk, Goedegebuure, Peter, Mach, Robert H, Hawkins, William G
Publicado em 2010

The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer

Por Hashim, Yassar M., Vangveravong, Suwanna, Sankpal, Narendra V., Binder, Pratibha S., Liu, Jingxia, Goedegebuure, S. Peter, Mach, Robert H., Spitzer, Dirk, Hawkins, William G.
Publicado no J Exp Clin Cancer Res (2017)

Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma

Por Kashiwagi, Hiroyuki, McDunn, Jonathan E, Simon, Peter O, Goedegebuure, Peter S, Vangveravong, Suwanna, Chang, Katherine, Hotchkiss, Richard S, Mach, Robert H, Hawkins, William G
Publicado em 2009

Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV‐134

Por Hashim, Yassar M., Spitzer, Dirk, Vangveravong, Suwanna, Hornick, Mary C., Garg, Gunjal, Hornick, John R., Goedegebuure, Peter, Mach, Robert H., Hawkins, William G.
Publicado em 2014

Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist

Por Xu, Jinbin, Vangveravong, Suwanna, Li, Shihong, Fan, Jinda, Jones, Lynne A., Cui, Jinquan, Wang, Ruike, Tu, Zhude, Chu, Wenhua, Perlmutter, Joel S., Mach, Robert H.
Publicado em 2013

Characterization and Evaluation of Two Novel Fluorescent Sigma-2 Receptor Ligands as Proliferation Probes

Por Zeng, Chenbo, Vangveravong, Suwanna, Jones, Lynne A., Hyrc, Krzysztof, Chang, Katherine C., Xu, Jinbin, Rothfuss, Justin M., Goldberg, Mark P., Hotchkiss, Richard S., Mach, Robert H.
Publicado no Mol Imaging (2011)

Comparison of the Binding and Functional Properties of Two Structurally Different D2 Dopamine Receptor Subtype Selective Compounds

Por Luedtke, Robert R., Mishra, Yogesh, Wang, Qi, Griffin, Suzy A., Bell-Horner, Cathy, Taylor, Michelle, Vangveravong, Suwanna, Dillon, Glenn H., Huang, Ren-Qi, Reichert, David E., Mach, Robert H.
Publicado em 2012

Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer

Por Garg, Gunjal, Vangveravong, Suwanna, Zeng, Chenbo, Collins, Lynne, Hornick, Mary, Hashim, Yassar, Piwnica-Worms, David, Powell, Matthew A, Mutch, David G, Mach, Robert H, Hawkins, William G, Spitzer, Dirk
Publicado em 2014